drugset / Trial / NCT02081625
Exploratory Study of NS-065/NCNP-01 in DMD
Phase 1
Completed
10 enrolled
National Center of Neurology and Psychiatry, Japan
Nippon Shinyaku Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This study is designed to assess the safety, tolerability, efficacy and pharmacokinetics (PK) of NS-065/NCNP-01 in subjects diagnosed with Duchenne muscular dystrophy (DMD).
Timeline
- Start
- 2013-06
- Primary completion
- 2014-11
- Completion
- 2015-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Viltolarsen | Unknown | 1.25 mg/kg | Intravenous |
| Subject | Viltolarsen | Unknown | 5 mg/kg | Intravenous |
| Subject | Viltolarsen | Unknown | 20 mg/kg | Intravenous |